Translocation t(9;11)(p21;q23) in pediatric de Novo and secondary acute myeloblastic leukemia

摘要: The t(9;11)(p21;q23) has been associated with characteristic clinical features and a superior treatment outcome in previously untreated pediatric acute myeloblastic leukemia (AML), but not well studied children secondary AML. This translocation was detected 6.7% of de novo 46% AML patients treated at St Jude Children's Research Hospital over an 11-year period. Clinical, immunophenotypic, morphologic characteristics were examined for the cases t(9;11) (n = 12) compared findings 12). Patients older diagnosis, had higher hemoglobin levels, central nervous system or hepatosplenomegaly less frequent. These differences probably reflect survival first malignancy close scrutiny during post-treatment follow-up. Whereas occurred exclusively French-American-British (FAB) M5 subtype AML, FAB M0 M4 subtypes also represented cases. complete remission rate somewhat group (91 vs 58%; p 0.16); their event-free clearly to that (p 0.003). Host related previous its could explain poorer Alternatively, there be critical site additional, hidden molecular events, different outcomes.